VAXDIGM
Latest round
- Series A
Last raised
- Oct 2024
Total raised
- $2M
Investors
- 7
About VAXDIGM
Based in Seoul, South Korea, and founded in 2021 by Seung-Hoo Kim, VAXDIGM operates as a biotechnology company that is focused on the research and development of vaccines. As of July, 2026, Kim Seong-jae is the CEO of the company. VAXDIGM uses the original technology for rapid vaccine production to develop improved vaccines and future vaccines, including twin-demic (COVID-19 & flu) vaccines. The firm offers cost-effective growth of artificial antigen vaccines using source technology for development and production using microorganisms rather than moth and animal cells.
Who invested in VAXDIGM
7 investors across 3 rounds
See all investors in VAXDIGM
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VAXDIGM
Who invested in VAXDIGM?
VAXDIGM has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VAXDIGM raised?
VAXDIGM has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did VAXDIGM last raise money?
VAXDIGM's most recent round on record is a Series A, in Oct 2024.
What does VAXDIGM do?
Based in Seoul, South Korea, and founded in 2021 by Seung-Hoo Kim, VAXDIGM operates as a biotechnology company that is focused on the research and development of vaccines.
Where is VAXDIGM headquartered?
VAXDIGM is headquartered in Seoul, South Korea.
Which VCs invest in companies like VAXDIGM?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at VAXDIGM's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like VAXDIGM? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.